Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Xiamen Innovax Biotech Co. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity involves 1 distinct examiner and 1 distinct art unit, showing a focused examination profile for the company's biotechnology filings.
The busiest examiner is JONES, DAMERON LEVEST, who is managing 1 pending office action. This 1 action represents the entire workload of 1 pending office action for the portfolio. This indicates that the company's current prosecution strategy is focused on the specific feedback of 1 examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253160 | ADJUVANT CONTAINING ZINC ALUMINUM RISEDRONATE, AND APPLICATION THEREOF | LY, KRISTINA ELISABETH | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253160 | ADJUVANT CONTAINING ZINC ALUMINUM RISEDRONATE, AND APPLICATION THEREOF | LY, KRISTINA ELISABETH | 40d |
| 17626351 | COMPLEX FOR INTRACELLULAR DELIVERY OF MOLECULES | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253160 | ADJUVANT CONTAINING ZINC ALUMINUM RISEDRONATE, AND APPLICATION THEREOF | LY, KRISTINA ELISABETH | 1671 | §102§103Other | Final Rejection | 40d | Pending | May 16, 2023 |
| 17626351 | COMPLEX FOR INTRACELLULAR DELIVERY OF MOLECULES | JONES, DAMERON LEVEST | 1618 | §112Other | Non-Final OA | — | Pending | Jan 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial